{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:34:34Z","timestamp":1790800474851,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Front. Med."],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s11684-022-0978-2","type":"journal-article","created":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:02:15Z","timestamp":1682899335000},"page":"729-746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Dihydroartemisinin increased the abundance of Akkermansia muciniphila by YAP1 depression that sensitizes hepatocellular carcinoma to anti-PD-1 immunotherapy"],"prefix":"10.1007","volume":"17","author":[{"given":"Zhiqin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinli","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmin","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinglin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caige","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,1]]},"reference":[{"issue":"11","key":"978_CR1","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/17474124.2021.1991792","volume":"15","author":"P Konyn","year":"2021","unstructured":"Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021; 15(11): 1295\u20131307","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"10088","key":"978_CR2","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH 3rd, Meyer T, Kang YK, Yeo W, Chopra A, Anderson J, Dela Cruz C, Lang L, Neely J, Tang H, Dastani HB, Melero I. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet 2017; 389(10088): 2492\u20132502","journal-title":"Lancet"},{"issue":"2","key":"978_CR3","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.jhep.2020.08.010","volume":"74","author":"CG Kim","year":"2021","unstructured":"Kim CG, Kim C, Yoon SE, Kim KH, Choi SJ, Kang B, Kim HR, Park SH, Shin EC, Kim YY, Kim DJ, Chung HC, Chon HJ, Choi HJ, Lim HY. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. J Hepatol 2021; 74(2): 350\u2013359","journal-title":"J Hepatol"},{"issue":"7","key":"978_CR4","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S1470-2045(18)30351-6","volume":"19","author":"AX Zhu","year":"2018","unstructured":"Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018; 19(7): 940\u2013952","journal-title":"Lancet Oncol"},{"issue":"6","key":"978_CR5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1136\/gutjnl-2017-315084","volume":"68","author":"Z Ren","year":"2019","unstructured":"Ren Z, Li A, Jiang J, Zhou L, Yu Z, Lu H, Xie H, Chen X, Shao L, Zhang R, Xu S, Zhang H, Cui G, Chen X, Sun R, Wen H, Lerut JP, Kan Q, Li L, Zheng S. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut 2019; 68(6): 1014\u20131023","journal-title":"Gut"},{"key":"978_CR6","doi-asserted-by":"crossref","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, Fidelle M, Flament C, Poirier-Colame V, Opolon P, Klein C, Iribarren K, Mondrag\u00f3n L, Jacquelot N, Qu B, Ferrere G, Cl\u00e9menson C, Mezquita L, Masip JR, Naltet C, Brosseau S, Kaderbhai C, Richard C, Rizvi H, Levenez F, Galleron N, Quinquis B, Pons N, Ryffel B, Minard-Colin V, Gonin P, Soria JC, Deutsch E, Loriot Y, Ghiringhelli F, Zalcman G, Goldwasser F, Escudier B, Hellmann MD, Eggermont A, Raoult D, Albiges L, Kroemer G, Zitvogel L. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018; 359(6371): 91\u201397","DOI":"10.1126\/science.aan3706"},{"issue":"6371","key":"978_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1126\/science.aao3290","volume":"359","author":"V Matson","year":"2018","unstructured":"Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ, Gajewski TF. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018; 359(6371): 104\u2013108","journal-title":"Science"},{"issue":"4","key":"978_CR8","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.eururo.2020.07.011","volume":"78","author":"NJ Salgia","year":"2020","unstructured":"Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J, Gillece JD, Folkerts M, Reining L, Trent J, Highlander SK, Pal SK. Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. Eur Urol 2020; 78(4): 498\u2013502","journal-title":"Eur Urol"},{"issue":"1","key":"978_CR9","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s40425-019-0650-9","volume":"7","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D, Jiang W, Cai S, Zhao P, Song R, Li P, Qin N, Fang W. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer 2019; 7(1): 193","journal-title":"J Immunother Cancer"},{"issue":"9","key":"978_CR10","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1002\/ijc.31561","volume":"143","author":"M Shibata","year":"2018","unstructured":"Shibata M, Ham K, Hoque MO. A time for YAP1: tumorigenesis, immunosuppression and targeted therapy. Int J Cancer 2018; 143(9): 2133\u20132144","journal-title":"Int J Cancer"},{"issue":"5","key":"978_CR11","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.jhep.2014.06.033","volume":"61","author":"A Perra","year":"2014","unstructured":"Perra A, Kowalik MA, Ghiso E, Ledda-Columbano GM, Di Tommaso L, Angioni MM, Raschioni C, Testore E, Roncalli M, Giordano S, Columbano A. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol 2014; 61(5): 1088\u20131096","journal-title":"J Hepatol"},{"issue":"1","key":"978_CR12","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/21655979.2020.1868119","volume":"12","author":"J Cao","year":"2021","unstructured":"Cao J, Zhang C, Jiang GQ, Jin SJ, Wang Q, Wang AQ, Bai DS. Identification of hepatocellular carcinoma-related genes associated with macrophage differentiation based on bioinformatics analyses. Bioengineered 2021; 12(1): 296\u2013309","journal-title":"Bioengineered"},{"issue":"6","key":"978_CR13","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.molcel.2021.01.010","volume":"81","author":"M Yu","year":"2021","unstructured":"Yu M, Peng Z, Qin M, Liu Y, Wang J, Zhang C, Lin J, Dong T, Wang L, Li S, Yang Y, Xu S, Guo W, Zhang X, Shi M, Peng H, Luo X, Zhang H, Zhang L, Li Y, Yang XP, Sun S. Interferon-\u03b3 induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation. Mol Cell 2021; 81(6): 1216\u20131230.e9","journal-title":"Mol Cell"},{"issue":"24","key":"978_CR14","doi-asserted-by":"publisher","first-page":"10641","DOI":"10.1007\/s00253-020-10976-3","volume":"104","author":"T Hagi","year":"2020","unstructured":"Hagi T, Geerlings SY, Nijsse B, Belzer C. The effect of bile acids on the growth and global gene expression profiles in Akkermansia muciniphila. Appl Microbiol Biotechnol 2020; 104(24): 10641\u201310653","journal-title":"Appl Microbiol Biotechnol"},{"issue":"7","key":"978_CR15","doi-asserted-by":"publisher","first-page":"e02766","DOI":"10.1128\/AEM.02766-16","volume":"83","author":"L Van den Bossche","year":"2017","unstructured":"Van den Bossche L, Hindryckx P, Devisscher L, Devriese S, Van Welden S, Holvoet T, Vilchez-Vargas R, Vital M, Pieper DH, Vanden Bussche J, Vanhaecke L, Van de Wiele T, De Vos M, Laukens D. Ursodeoxycholic acid and its taurine- or glycine-conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice. Appl Environ Microbiol 2017; 83(7): e02766\u201316","journal-title":"Appl Environ Microbiol"},{"issue":"1","key":"978_CR16","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12915-017-0462-7","volume":"15","author":"X Zheng","year":"2017","unstructured":"Zheng X, Huang F, Zhao A, Lei S, Zhang Y, Xie G, Chen T, Qu C, Rajani C, Dong B, Li D, Jia W. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice. BMC Biol 2017; 15(1): 120","journal-title":"BMC Biol"},{"issue":"4","key":"978_CR17","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.celrep.2013.10.030","volume":"5","author":"S Anakk","year":"2013","unstructured":"Anakk S, Bhosale M, Schmidt VA, Johnson RL, Finegold MJ, Moore DD. Bile acids activate YAP to promote liver carcinogenesis. Cell Rep 2013; 5(4): 1060\u20131069","journal-title":"Cell Rep"},{"issue":"5","key":"978_CR18","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.7150\/jca.36174","volume":"11","author":"T Wang","year":"2020","unstructured":"Wang T, Luo R, Li W, Yan H, Xie S, Xiao W, Wang Y, Chen B, Bai P, Xing J. Dihydroartemisinin suppresses bladder cancer cell invasion and migration by regulating KDM3A and p21. J Cancer 2020; 11(5): 1115\u20131124","journal-title":"J Cancer"},{"key":"978_CR19","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.2147\/OTT.S297785","volume":"14","author":"Q Li","year":"2021","unstructured":"Li Q, Ma Q, Cheng J, Zhou X, Pu W, Zhong X, Guo X. Dihydroartemisinin as a sensitizing agent in cancer therapies. OncoTargets Ther 2021; 14: 2563\u20132573","journal-title":"OncoTargets Ther"},{"issue":"1\u20132","key":"978_CR20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cell.2011.11.026","volume":"148","author":"Z Li","year":"2012","unstructured":"Li Z, Tuteja G, Schug J, Kaestner KH. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 2012; 148(1\u20132): 72\u201383","journal-title":"Cell"},{"issue":"7686","key":"978_CR21","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X, Guo J, Huang YH, Fan C, Ren S, Sun Y, Freeman GJ, Sicinski P, Wei W. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 2018; 553(7686): 91\u201395","journal-title":"Nature"},{"issue":"8","key":"978_CR22","doi-asserted-by":"publisher","first-page":"e139434","DOI":"10.1172\/JCI139434","volume":"131","author":"Z Jiang","year":"2021","unstructured":"Jiang Z, Lim SO, Yan M, Hsu JL, Yao J, Wei Y, Chang SS, Yamaguchi H, Lee HH, Ke B, Hsu JM, Chan LC, Hortobagyi GN, Yang L, Lin C, Yu D, Hung MC. TYRO3 induces anti-PD-1\/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. J Clin Invest 2021; 131(8): e139434","journal-title":"J Clin Invest"},{"key":"978_CR23","doi-asserted-by":"publisher","first-page":"153913","DOI":"10.1016\/j.phymed.2021.153913","volume":"96","author":"L Hao","year":"2022","unstructured":"Hao L, Guo Y, Peng Q, Zhang Z, Ji J, Liu Y, Xue Y, Li C, Zheng K, Shi X. Dihydroartemisinin reduced lipid droplet deposition by YAP1 to promote the anti-PD-1 effect in hepatocellular carcinoma. Phytomedicine 2022; 96: 153913","journal-title":"Phytomedicine"},{"issue":"6","key":"978_CR24","doi-asserted-by":"publisher","first-page":"e22361","DOI":"10.1096\/fj.202200171R","volume":"36","author":"Y Guo","year":"2022","unstructured":"Guo Y, Peng Q, Hao L, Ji J, Zhang Z, Xue Y, Liu Y, Gao Y, Li C, Shi X. Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma. FASEB J 2022; 36(6): e22361","journal-title":"FASEB J"},{"issue":"24","key":"978_CR25","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1161\/CIRCULATIONAHA.115.019645","volume":"133","author":"J Li","year":"2016","unstructured":"Li J, Lin S, Vanhoutte PM, Woo CW, Xu A. Akkermansia muciniphila protects against atherosclerosis by preventing metabolic endotoxemia-induced inflammation in Apoe\u2212\/\u2212 mice. Circulation 2016; 133(24): 2434\u20132446","journal-title":"Circulation"},{"issue":"23","key":"978_CR26","doi-asserted-by":"publisher","first-page":"7767","DOI":"10.1128\/AEM.01477-07","volume":"73","author":"MC Collado","year":"2007","unstructured":"Collado MC, Derrien M, Isolauri E, de Vos WM, Salminen S. Intestinal integrity and Akkermansia muciniphila, a mucin-degrading member of the intestinal microbiota present in infants, adults, and the elderly. Appl Environ Microbiol 2007; 73(23): 7767\u20137770","journal-title":"Appl Environ Microbiol"},{"issue":"22","key":"978_CR27","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1128\/AEM.01343-09","volume":"75","author":"R Pieper","year":"2009","unstructured":"Pieper R, Bindelle J, Rossnagel B, Van Kessel A, Leterme P. Effect of carbohydrate composition in barley and oat cultivars on microbial ecophysiology and proliferation of Salmonella enterica in an in vitro model of the porcine gastrointestinal tract. Appl Environ Microbiol 2009; 75(22): 7006\u20137016","journal-title":"Appl Environ Microbiol"},{"issue":"11","key":"978_CR28","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1136\/gutjnl-2019-320105","volume":"69","author":"L Wang","year":"2020","unstructured":"Wang L, Tang L, Feng Y, Zhao S, Han M, Zhang C, Yuan G, Zhu J, Cao S, Wu Q, Li L, Zhang Z. A purified membrane protein from Akkermansia muciniphila or the pasteurised bacterium blunts colitis associated tumourigenesis by modulation of CD8+ T cells in mice. Gut 2020; 69(11): 1988\u20131997","journal-title":"Gut"},{"issue":"2","key":"978_CR29","doi-asserted-by":"publisher","first-page":"597","DOI":"10.3892\/ol.2021.12858","volume":"22","author":"X Jiu","year":"2021","unstructured":"Jiu X, Liu Y, Wen J. Artesunate combined with verteporfin inhibits uveal melanoma by regulation of the MALAT1\/yes-associated protein signaling pathway. Oncol Lett 2021; 22(2): 597","journal-title":"Oncol Lett"},{"key":"978_CR30","doi-asserted-by":"publisher","first-page":"119729","DOI":"10.1016\/j.lfs.2021.119729","volume":"280","author":"R Liu","year":"2021","unstructured":"Liu R, Choi HS, Ko YC, Yun BS, Lee DS. 5-Desmethylsinensetin isolated from Artemisia princeps suppresses the stemness of breast cancer cells via Stat3\/IL-6 and Stat3\/YAP1 signaling. Life Sci 2021; 280: 119729","journal-title":"Life Sci"},{"issue":"6371","key":"978_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1126\/science.aan4236","volume":"359","author":"V Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018; 359(6371): 97\u2013103","journal-title":"Science"},{"issue":"24","key":"978_CR32","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1097\/CM9.0000000000001887","volume":"134","author":"ZY Gao","year":"2021","unstructured":"Gao ZY, Cui Z, Yan YQ, Ning LJ, Wang ZH, Hong J. Microbe-based management for colorectal cancer. Chin Med J (Engl) 2021; 134(24): 2922\u20132930","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"978_CR33","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41391-018-0061-x","volume":"21","author":"KS Sfanos","year":"2018","unstructured":"Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ, Antonarakis ES, Ross AE. Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis 2018; 21(4): 539\u2013548","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"978_CR34","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13099-020-00381-6","volume":"12","author":"PL Miller","year":"2020","unstructured":"Miller PL, Carson TL. Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review. Gut Pathog 2020; 12(1): 43","journal-title":"Gut Pathog"},{"issue":"10","key":"978_CR35","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1158\/1055-9965.EPI-19-0008","volume":"28","author":"EJ Snider","year":"2019","unstructured":"Snider EJ, Compres G, Freedberg DE, Khiabanian H, Nobel YR, Stump S, Uhlemann AC, Lightdale CJ, Abrams JA. Alterations to the esophageal microbiome associated with progression from Barrett\u2019s esophagus to esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2019; 28(10): 1687\u20131693","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"978_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2049-2618-2-20","volume":"2","author":"NT Baxter","year":"2014","unstructured":"Baxter NT, Zackular JP, Chen GY, Schloss PD. Structure of the gut microbiome following colonization with human feces determines colonic tumor burden. Microbiome 2014; 2(1): 20","journal-title":"Microbiome"},{"issue":"1","key":"978_CR37","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1038\/s41598-021-82465-0","volume":"11","author":"MA Osman","year":"2021","unstructured":"Osman MA, Neoh HM, Ab Mutalib NS, Chin SF, Mazlan L, Raja Ali RA, Zakaria AD, Ngiu CS, Ang MY, Jamal R. Parvimonas micra, Peptostreptococcus stomatis, Fusobacterium nucleatum and Akkermansia muciniphila as a four-bacteria biomarker panel of colorectal cancer. Sci Rep 2021; 11(1): 2925","journal-title":"Sci Rep"},{"issue":"1","key":"978_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.7150\/jca.63578","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang F, Cai K, Xiao Q, He L, Xie L, Liu Z. Akkermansia muciniphila administration exacerbated the development of colitis-associated colorectal cancer in mice. J Cancer 2022; 13(1): 124\u2013133","journal-title":"J Cancer"},{"issue":"4","key":"978_CR39","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.eururo.2018.05.033","volume":"74","author":"M Santoni","year":"2018","unstructured":"Santoni M, Piva F, Conti A, Santoni A, Cimadamore A, Scarpelli M, Battelli N, Montironi R. Re: gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Eur Urol 2018; 74(4): 521\u2013522","journal-title":"Eur Urol"},{"key":"978_CR40","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.2147\/IJN.S304515","volume":"16","author":"ZW Luo","year":"2021","unstructured":"Luo ZW, Xia K, Liu YW, Liu JH, Rao SS, Hu XK, Chen CY, Xu R, Wang ZX, Xie H. Extracellular vesicles from Akkermansia muciniphila elicit antitumor immunity against prostate cancer via modulation of CD8+ T cells and macrophages. Int J Nanomedicine 2021; 16: 2949\u20132963","journal-title":"Int J Nanomedicine"},{"issue":"5","key":"978_CR41","doi-asserted-by":"publisher","first-page":"G493","DOI":"10.1152\/ajpgi.00056.2011","volume":"302","author":"S Septer","year":"2012","unstructured":"Septer S, Edwards G, Gunewardena S, Wolfe A, Li H, Daniel J, Apte U. Yes-associated protein is involved in proliferation and differentiation during postnatal liver development. Am J Physiol Gastrointest Liver Physiol 2012; 302(5): G493\u2013G503","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"978_CR42","doi-asserted-by":"publisher","first-page":"6239","DOI":"10.1038\/ncomms7239","volume":"6","author":"H Wu","year":"2015","unstructured":"Wu H, Wei L, Fan F, Ji S, Zhang S, Geng J, Hong L, Fan X, Chen Q, Tian J, Jiang M, Sun X, Jin C, Yin ZY, Liu Q, Zhang J, Qin F, Lin KH, Yu JS, Deng X, Wang HR, Zhao B, Johnson RL, Chen L, Zhou D. Integration of Hippo signalling and the unfolded protein response to restrain liver overgrowth and tumorigenesis. Nat Commun 2015; 6(1): 6239","journal-title":"Nat Commun"},{"issue":"8","key":"978_CR43","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1002\/ijc.30219","volume":"139","author":"G Xie","year":"2016","unstructured":"Xie G, Wang X, Huang F, Zhao A, Chen W, Yan J, Zhang Y, Lei S, Ge K, Zheng X, Liu J, Su M, Liu P, Jia W. Dysregulated hepatic bile acids collaboratively promote liver carcinogenesis. Int J Cancer 2016; 139(8): 1764\u20131775","journal-title":"Int J Cancer"},{"issue":"4","key":"978_CR44","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1002\/hep.1840400427","volume":"40","author":"Y Fang","year":"2004","unstructured":"Fang Y, Han SI, Mitchell C, Gupta S, Studer E, Grant S, Hylemon PB, Dent P. Bile acids induce mitochondrial ROS, which promote activation of receptor tyrosine kinases and signaling pathways in rat hepatocytes. Hepatology 2004; 40(4): 961\u2013971","journal-title":"Hepatology"},{"issue":"14","key":"978_CR45","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.3748\/wjg.15.1677","volume":"15","author":"MJ Perez","year":"2009","unstructured":"Perez MJ, Briz O. Bile-acid-induced cell injury and protection. World J Gastroenterol 2009; 15(14): 1677\u20131689","journal-title":"World J Gastroenterol"},{"issue":"2","key":"978_CR46","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/hep.29561","volume":"67","author":"P Luo","year":"2018","unstructured":"Luo P, Yin P, Hua R, Tan Y, Li Z, Qiu G, Yin Z, Xie X, Wang X, Chen W, Zhou L, Wang X, Li Y, Chen H, Gao L, Lu X, Wu T, Wang H, Niu J, Xu G. A large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma. Hepatology 2018; 67(2): 662\u2013675","journal-title":"Hepatology"},{"issue":"7","key":"978_CR47","doi-asserted-by":"publisher","first-page":"M110.004945","DOI":"10.1074\/mcp.M110.004945","volume":"10","author":"T Chen","year":"2011","unstructured":"Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, Qi X, Cao Y, Su M, Wang X, Xu LX, Yen Y, Liu P, Jia W. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 2011; 10(7): M110.004945","journal-title":"Mol Cell Proteomics"},{"issue":"3","key":"978_CR48","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/jnci\/djz122","volume":"112","author":"E Loftfield","year":"2020","unstructured":"Loftfield E, Rothwell JA, Sinha R, Keski-Rahkonen P, Robinot N, Albanes D, Weinstein SJ, Derkach A, Sampson J, Scalbert A, Freedman ND. Prospective investigation of serum metabolites, coffee drinking, liver cancer incidence, and liver disease mortality. J Natl Cancer Inst 2020; 112(3): 286\u2013294","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"978_CR49","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/microorganisms6030075","volume":"6","author":"SY Geerlings","year":"2018","unstructured":"Geerlings SY, Kostopoulos I, de Vos WM, Belzer C. Akkermansia muciniphila in the human gastrointestinal tract: when, where, and how? Microorganisms 2018; 6(3): 75","journal-title":"Microorganisms"},{"issue":"3","key":"978_CR50","doi-asserted-by":"publisher","first-page":"e1007581","DOI":"10.1371\/journal.ppat.1007581","volume":"15","author":"MH Foley","year":"2019","unstructured":"Foley MH, O\u2019Flaherty S, Barrangou R, Theriot CM. Bile salt hydrolases: gatekeepers of bile acid metabolism and host-microbiome crosstalk in the gastrointestinal tract. PLoS Pathog 2019; 15(3): e1007581","journal-title":"PLoS Pathog"},{"issue":"5","key":"978_CR51","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.18632\/aging.202739","volume":"13","author":"C Grajeda-Iglesias","year":"2021","unstructured":"Grajeda-Iglesias C, Durand S, Daill\u00e8re R, Iribarren K, Lemaitre F, Derosa L, Aprahamian F, Bossut N, Nirmalathasan N, Madeo F, Zitvogel L, Kroemer G. Oral administration of Akkermansia muciniphila elevates systemic antiaging and anticancer metabolites. Aging (Albany NY) 2021; 13(5): 6375\u20136405","journal-title":"Aging (Albany NY)"}],"container-title":["Frontiers of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-022-0978-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11684-022-0978-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-022-0978-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T01:09:41Z","timestamp":1697245781000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11684-022-0978-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,1]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["978"],"URL":"https:\/\/doi.org\/10.1007\/s11684-022-0978-2","relation":{},"ISSN":["2095-0217","2095-0225"],"issn-type":[{"value":"2095-0217","type":"print"},{"value":"2095-0225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,1]]},"assertion":[{"value":"7 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zhiqin Zhang, Xinli Shi, Jingmin Ji, Yinglin Guo, Qing Peng, Liyuan Hao, Yu Xue, Yiwei Liu, Caige Li, Junlan Lu, and Kun Yu declare that they have no conflict of interest. All institutional and national guidelines for the care and use of laboratory animals were followed.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}